T1	Condition 680 704	noncommunicable diseases
T2	Condition-Name 680 704	noncommunicable diseases
E1	Condition:T1 Name:T2
T3	Condition 297 320	endometrial hyperplasia
T4	Condition-Name 297 320	endometrial hyperplasia
E3	Condition:T3 Name:T4
T5	Condition 106 123	vaginal infection
T6	Condition-Name 106 123	vaginal infection
E5	Condition:T5 Name:T6 Temporality:E17
T7	Condition 215 232	vaginal infection
T8	Condition-Name 215 232	vaginal infection
E7	Condition:T7 Name:T8
T9	Condition 706 723	diabetes mellitus
T10	Condition-Name 706 723	diabetes mellitus
E9	Condition:T9 Name:T10
T11	Condition 725 738	heart disease
T12	Condition-Name 725 738	heart disease
E11	Condition:T11 Name:T12
T13	Condition 385 396	intolerance
T14	Condition-Name 385 396	intolerance
E13	Condition:T13 Name:T14
T15	Condition 646 652	sepsis
T16	Condition-Name 646 652	sepsis
E15	Condition:T15 Name:T16
T17	Eq-Temporal-Unit 57 62	years
A1	Eq-Temporal-Unit-Value T17 year
T18	Age 63 66	old
E16	Age:T18 Eq-Comparison:E4
T19	Eq-Value 47 49	18
T20	Eq-Value 54 56	45
T21	Eq-Comparison 86 93	current
E17	Eq-Comparison:T21 Temporal-Period:T22
T22	Eq-Temporal-Period 86 93	current
A2	Eq-Temporal-Period-Value T22 present
T23	Eq-Comparison 352 358	active
E18	Eq-Comparison:T23 Temporal-Period:T24
T24	Eq-Temporal-Period 352 358	active
A3	Eq-Temporal-Period-Value T24 present
T25	Eq-Comparison 536 551	currently using
E19	Eq-Comparison:T25 Temporal-Period:T26
T26	Eq-Temporal-Period 536 551	currently using
A4	Eq-Temporal-Period-Value T26 present
T29	Eq-Comparison 613 618	using
E21	Eq-Comparison:T29 Temporal-Period:T30
T30	Eq-Temporal-Period 613 618	using
A6	Eq-Temporal-Period-Value T30 present
T31	Condition 25 32	Healthy
E2	Condition:T31 Name:T32
T32	Condition-Name 25 32	Healthy
T33	Life-Stage-And-Gender 33 38	women
A7	Life-Stage-And-Gender-Type T33 female
T34	Eq-Comparison 39 62	between 18 and 45 years
E4	Eq-Comparison:T34 Value:T19 Temporal-Unit:T17 Value2:T20
T35	Life-Stage-And-Gender 72 77	Women
A8	Life-Stage-And-Gender-Type T35 female
T36	Assertion 94 102	symptoms
E6	Assertion:T36 Asserted:E5
A9	Assertion-Type-Value E6 possible
T37	Negation 78 85	without
E8	Negation:T37 Negates:E5
T38	Procedure 167 178	examination
E10	Procedure:T38 Name:T39 Polarity:T43
T39	Procedure-Name 167 178	examination
T40	Modifier 158 166	clinical
E12	Modifier:T40 Modifies:T39
T41	Modifier 138 153	bacteriological
E14	Modifier:T41 Modifies:T39
T42	And 154 157	and
E22	And:T42 Arg:E14 Arg2:E12
T43	Polarity 129 137	Negative
A10	Polarity-Value T43 negative
T44	Life-Stage-And-Gender 204 209	Women
A11	Life-Stage-And-Gender-Type T44 female
T45	And 210 214	with
E23	And:T45 Arg:T44 Arg2:E7
T46	Condition 261 277	vaginal bleeding
E24	Condition:T46 Name:T47
T47	Condition-Name 261 277	vaginal bleeding
T48	Life-Stage-And-Gender 238 243	Women
A12	Life-Stage-And-Gender-Type T48 female
T49	And 244 248	with
E25	And:T49 Arg:T48 Arg2:E24
T50	Assertion 326 335	Suspicion
E26	Assertion:T50 Asserted:E28
A13	Assertion-Type-Value E26 possible
T51	Condition 359 368	neoplasia
E27	Condition:T51 Name:T52 Temporality:E18
T52	Condition-Name 359 368	neoplasia
T53	Condition 339 348	neoplasia
E28	Condition:T53 Name:T54
T54	Condition-Name 339 348	neoplasia
T55	Or 349 351	or
E29	Or:T55 Arg:E28 Arg2:E27
T56	Life-Stage-And-Gender 374 379	Women
A14	Life-Stage-And-Gender-Type T56 female
T57	Drug 451 460	probiotic
E30	Drug:T57 Name:T58
T58	Drug-Name 451 460	probiotic
T59	Condition 409 425	hypersensitivity
E31	Condition:T59 Name:T60
T60	Condition-Name 409 425	hypersensitivity
T61	Allergy 398 405	allergy
E32	Allergy:T61 Name:E30
R1	Caused-By Arg1:E31 Arg2:E30	
T62	Or 406 408	or
E33	Or:T62 Arg:E32 Arg2:E31
R2	Caused-By Arg1:E13 Arg2:E30	
T63	And 380 384	with
E34	And:T63 Arg:T56 Arg2:E13
T64	Life-Stage-And-Gender 466 471	Women
A15	Life-Stage-And-Gender-Type T64 female
T65	Condition 477 504	immunosuppressive disorders
E35	Condition:T65 Name:T66
T66	Condition-Name 477 504	immunosuppressive disorders
T67	Condition 513 516	HIV
E36	Condition:T67 Name:T68
T68	Condition-Name 513 516	HIV
T69	Or 505 507	or
E37	Or:T69 Arg:E35 Arg2:E36
T70	And 472 476	with
E38	And:T70 Arg:T64 Arg2:E35
T71	Life-Stage-And-Gender 522 527	Women
A16	Life-Stage-And-Gender-Type T71 female
T27	Drug 552 562	probiotics
E20	Drug:T27 Name:T28 Temporality:E19
T28	Drug-Name 552 562	probiotics
T72	And 528 531	who
E39	And:T72 Arg:T71 Arg2:E20
T73	Life-Stage-And-Gender 599 604	Women
A5	Life-Stage-And-Gender-Type T73 female
T74	And 605 608	who
E40	And:T74 Arg:T73 Arg2:E41
T75	Procedure 624 633	treatment
E41	Procedure:T75 Temporality:E21
R3	Treatment-For Arg1:E41 Arg2:E15	
T76	Modifier 638 645	vaginal
E42	Modifier:T76 Modifies:T16
T77	Modifier 666 679	decompensated
E43	Modifier:T77 Modifies:E1
T78	Modifier 658 665	Chronic
E44	Modifier:T78 Modifies:E1
R4	Example-Of Arg1:E9 Arg2:E1	
R5	Example-Of Arg1:E11 Arg2:E1	
T79	Condition 749 757	Pregnant
E45	Condition:T79 Name:T80
T80	Condition-Name 749 757	Pregnant
T81	Life-Stage-And-Gender 758 763	women
A17	Life-Stage-And-Gender-Type T81 female
R6	If-Then Arg1:T81 Arg2:E45	
T82	Condition 778 798	precocious menopause
E46	Condition:T82 Name:T83
T83	Condition-Name 778 798	precocious menopause
T84	Or 764 766	or
E47	Or:T84 Arg:T81 Arg2:E46
